Want to see TSE:OGI full AI Analyst Report?
Organigram Global (OGI) AI Stock Analysis
Top Page
Organigram Global
(TSX:OGI)
The score reflects improving growth and a low-debt balance sheet, plus supportive technical momentum and upbeat FY2026 guidance. Offsetting these positives are weak underlying operating profitability (negative gross and operating margins) and ongoing cash burn/negative free cash flow (including management’s expectation of full-year negative FCF), which materially raise execution and funding-risk considerations.
Organigram Global (OGI) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 131.57M
- Dividend Yield
- ―
- Average Volume (3M)
- 137.12K
- Price to Earnings (P/E)
- 2.1
- Beta (1Y)
- 1.83
- Revenue Growth
- 38.14%
- EPS Growth
- 2030.00%
- Country
- Canada
- Employees
- 1,139
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Organigram Global Business Overview & Revenue Model
Company Description
Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and co...
How the Company Makes Money
Organigram primarily makes money by manufacturing and selling regulated cannabis products and related services in markets where cannabis is legal. Its key revenue streams include: (1) Adult-use (recreational) cannabis sales in Canada: the company sel...
Organigram Global Earnings Call Summary
The call communicated strong operational and financial momentum driven largely by the Sanity acquisition: record revenue, margin expansion, record adjusted EBITDA, and meaningful international diversification. Operational improvements in cultivation and category share gains in Canada reinforce the positive narrative. Key risks include negative free cash flow driven by working capital build, pending EU-GMP certification and tight EU-GMP supply into Germany, earlier vape/pre-roll quality issues in Canada, and U.S. regulatory uncertainty. Net income was materially boosted by non-cash fair value gains, so underlying cash generation and integration-related working capital remain focal concerns. On balance, the positive financial results, strategic diversification, and improving margin trajectory outweigh the liquidity and regulatory challenges discussed.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided full‑year fiscal 2026 revenue to exceed $350 million, with adjusted gross margin and adjusted EBITDA expected to meaningfully exceed fiscal 2025 levels; they reiterated Sanity is expected to average ~EUR 25 million of quarterly revenue (Sanity delivered EUR 24.5M since April 15 and EUR 25.5M for the full quarter), international sales now constitute ~35% of consolidated revenue (vs ~10% pre‑acquisition), and they expect Q4 to outperform Q3. They cautioned that working‑capital investments tied to the Sanity integration will result in negative free cash flow for the full year (Q3 free cash flow was an outflow of $3.9M) but forecast positive free cash flow in Q4; Q3 results underpinning the outlook included record net revenue of $105.8M, adjusted gross margin of 37% (+300 bps YoY, +600 bps QoQ), record adjusted EBITDA of $13.4M, cash & equivalents of $11.7M and total liquidity of $49.2M. Management also noted Sanity margins are in line with expectations, Germany demand remains strong with minimal price compression, and that achieving EU‑GMP would meaningfully improve margins going forward.
Organigram Global Financial Statement Overview
Summary
Mixed fundamentals. Revenue is growing (TTM 309.2M, +12.8%), and leverage is low (debt-to-equity ~0.06) with expanding equity. However, operating quality remains weak with negative gross margin (-5.7%) and negative EBIT/EBITDA margins, and cash generation is a major concern with negative operating cash flow (-27.9M) and negative free cash flow (-29.1M).
Income Statement
44NeutralBalance Sheet
78PositiveCash Flow
32Negative| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Aug 2022 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 309.18M | 259.18M | 159.84M | 149.21M | 145.81M | 79.16M |
| Gross Profit | 6.87M | 9.51M | 47.52M | 35.07M | 31.57M | -28.40M |
| EBITDA | -28.07M | -20.55M | -23.59M | -207.62M | 10.96M | -95.59M |
| Net Income | 86.62M | -24.76M | -45.44M | -229.48M | -14.28M | -130.70M |
Balance Sheet | ||||||
| Total Assets | 820.26M | 562.21M | 407.86M | 298.45M | 577.11M | 554.02M |
| Cash, Cash Equivalents and Short-Term Investments | 11.67M | 84.42M | 107.57M | 33.86M | 98.91M | 183.84M |
| Total Debt | 31.45M | 8.75M | 4.46M | 4.72M | 3.36M | 4.96M |
| Total Liabilities | 334.80M | 213.08M | 101.87M | 26.83M | 69.05M | 74.21M |
| Stockholders Equity | 485.46M | 349.13M | 305.99M | 271.62M | 508.06M | 479.81M |
Cash Flow | ||||||
| Free Cash Flow | -29.06M | -24.64M | -1.47M | -62.70M | -84.99M | -40.92M |
| Operating Cash Flow | -27.93M | -7.59M | 3.87M | -35.80M | -36.21M | -28.59M |
| Investing Cash Flow | -130.20M | -82.67M | -38.77M | 1.35M | 44.03M | -115.11M |
| Financing Cash Flow | 83.66M | 39.33M | 107.78M | -817.00K | 5.33M | 174.46M |
Organigram Global Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OGI, the sentiment is Negative. The current price of 1.32 is below the 20-day moving average (MA) of 1.34, below the 50-day MA of 1.47, and below the 200-day MA of 1.67, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 41.53 is Neutral, neither overbought nor oversold. The STOCH value of 73.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:OGI.
Organigram Global Peers Comparison
Overall Rating
TSE:CRON80Outperform
TSE:GTII73Outperform- TSE:OGI61Neutral
TSE:CURA59Neutral
TSE:ACB54Neutral
TSE:WEED48Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:CRON | 80Outperform | CAD 1.70B | 17.61 | 6.46% | ― | 36.21% | 264.71% |
| TSE:GTII | 73Outperform | CAD 1.90B | 11.41 | 6.82% | ― | 3.81% | 344.13% |
| TSE:OGI | 61Neutral | CAD 186.13M | 2.05 | 21.99% | ― | 38.14% | 2030.00% |
| TSE:CURA | 59Neutral | CAD 3.12B | -60.28 | -4.47% | ― | 1.50% | 81.84% |
| TSE:ACB | 54Neutral | CAD 372.12M | -2.93 | -21.00% | ― | -18.93% | -472.15% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:WEED | 48Neutral | CAD 414.62M | -1.39 | -29.85% | ― | 6.81% | 85.26% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:OGI | Organigram Global Inc. | 1.32 | -0.88 | -40.00% | |
| TSE:WEED | Canopy Growth | 0.93 | -0.77 | -45.29% | |
| TSE:ACB | Aurora Cannabis (US) | 5.66 | -1.20 | -17.49% | |
| TSE:CRON | Cronos Group (US) | 4.62 | 1.06 | 29.78% | |
| TSE:CURA | Curaleaf Holdings (Otc) | 11.77 | 0.04 | 0.34% | |
| TSE:GTII | Green Thumb Industries (OTC) | 8.70 | -0.95 | -9.84% |
Organigram Global Corporate Events
Organigram Streamlines Global Operations After Sanity Group Integration to Boost Profitability
PositiveOrganigram Global is consolidating Sanity Group into a single unified enterprise and overhauling its operating model to place profitability at the centre of its global cannabis platform. The company is streamlining Canadian manufacturing and global f...
Organigram to Stream 2026 Investor Session as It Expands Cannabis Footprint
PositiveOrganigram Global Inc., a dual-listed cannabis cultivator and processor on NASDAQ and TSX, is expanding its footprint across Canada and Europe with a broad portfolio of adult-use and medical cannabis brands. Through multiple facilities in New Brunswi...
Organigram Speeds Sanity Group Integration to Build Unified Global Cannabis Platform
PositiveOrganigram Global is accelerating the integration of Germany-based Sanity Group into a unified global operating structure that links its Canadian production with European commercial and regulatory capabilities. The combined supply and commercial netw...
Organigram Posts Record Q3 2026 Results on Sanity Group-Driven Global Expansion
PositiveOrganigram reported record third-quarter fiscal 2026 results, driven largely by its recent acquisition of Sanity Group, with gross revenue rising 32% year over year to $145.1 million and net revenue climbing 49% to $105.8 million. Adjusted EBITDA mor...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026